Pure Global AI
NCT06243510Enrolling by invitation

Comparison of Apixaban Versus Enoxaparin

Comparison of Apixaban Versus Enoxaparin as Venous Thromboembolism Prophylaxis After Radical Cystectomy
Abramson Cancer Center at Penn MedicineClinicalTrials.govother
Verified
Study focus
Disease/Condition
Bladder Cancer
Drug/Device/Intervention
apixaban
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Abramson Cancer Center at Penn Medicine
Location
Philadelphia, United States of America
Timeline & enrollment
Phase
N/A
Start date
Nov 24, 2023
End date
Jul 01, 2025
Enrollment
90 participants
Primary outcome

Adherence

Summary

The goal of this randomized trial is to compare bladder cancer patient experiences taking
 prophylactic anticoagulation at home after surgery to remove their bladder. The main
 questions it aims to answer are:
 
 - Are patients equally adherent to apixaban as they are enoxaparin? Why or why not?
 
 - Do patients prefer apixaban or enoxaparin?
 
 - What is the typical patient cost to take apixaban vs enoxaparin after surgery?
 
 Participants will be randomized to receive a prescription for either enoxaparin or apixaban
 which they will then fill themselves and self-administer at home until post-operative day 30.
 They will receive phone calls from study coordinators at days 30 and 90 to complete
 questionaries over the phone to assess trial outcomes.

ICD-10 classifications
Malignant neoplasm of bladderMalignant neoplasm: Bladder, unspecifiedMalignant neoplasm: Dome of bladderMalignant neoplasm: Overlapping lesion of bladderMalignant neoplasm: Lateral wall of bladder
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06243510
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06243510 through Pure Global AI's free database. This phase not specified trial is sponsored by Abramson Cancer Center at Penn Medicine and is currently Enrolling by invitation. The study focuses on Bladder Cancer. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.